Phase 2 Mesothelioma Trial, Recruiting NCT05086692 Sponsor: Medicenna Therapeutics, Inc. Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT05086692
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are fairly active and able to care for yourself, with little or no limitation on daily activities (this is measured by a standard scale called ECOG, scored 0 or 1)
  • You are willing and able to sign a consent form and follow all study requirements
  • Your cancer has been confirmed by a lab test (biopsy or similar) and has either spread to nearby tissue or to other parts of the body
  • Your major organs (such as liver, kidneys, and bone marrow) are working well enough
  • Your cancer can be measured on a scan (CT or MRI)
  • Your doctor expects you to live for at least 12 weeks
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before starting the study
  • You agree to use highly effective birth control during the study (required for women who could become pregnant)

Who may not be able to join:

  • You have received cancer treatment, chemotherapy, or been in another clinical trial within the last 4 weeks (or a shorter period for certain targeted therapies — confirm with trial site)
  • You have had radiation therapy within the last 2 weeks, or have a history of lung inflammation caused by radiation
  • You have had high-dose radiation to the lungs (over 30Gy) within the last 6 months
  • Your cancer has spread to the brain and is currently active; however, previously treated and stable brain metastases may be considered (confirm with trial site)
  • You have had another cancer within the last 3 years, unless it was a type that has been fully cured
  • You are taking steroid medicines (such as prednisone) at higher doses long-term, or other medicines that suppress your immune system
  • You have a significant active autoimmune disease (where your immune system attacks your own body), or a condition that could get worse with immune-based treatments
  • You have serious heart, lung, or other major organ disease
  • You have a known hepatitis B or hepatitis C infection
  • You are pregnant, breastfeeding, or planning to become pregnant during the study
  • You have previously received an organ or tissue transplant from another person
  • You currently have an active infection that requires treatment with antibiotics or other medicines
  • You have a mental health, emotional, or other medical condition that might make it hard to follow the study requirements
  • You have a known serious allergy to any ingredient in the study drug(s)
  • In the opinion of the study doctor, any other medical condition that could make the treatment unsafe or make results difficult to interpret

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nina Merchant, Medicenna Therapeutics

Phone: 604-340-3081

Australian sites

Scientia Clinical Research, Randwick, New South Wales
Macquarie University, Sydney, New South Wales
University of the Sunshine Coast, Buderim, Queensland
Gallipoli Medical Research Foundation, Greenslopes, Queensland

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Medicenna Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
27 August 2021
Est. completion
30 June 2026

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇮🇪 Ireland 🇵🇹 Portugal 🇰🇷 South Korea 🇪🇸 Spain 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE); Incidence of Treatment Related Adverse Events (TRAEs); Incidence of Treatment Emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov